Track the 젠큐릭스 stock price and the full directors' dealings record of the company, a publicly traded company based in South Korea. Shares are listed on the KR market, under the authority of DART (FSS). Operating in the Health Care sector, 젠큐릭스 has logged 49 public disclosures. Market capitalisation: €36.9bn. The latest transaction was disclosed on 5 June 2026 (Purchase). Among the most active insiders: 조상래. Every trade is openly available.
49
Insider Decl.
n/a
Thresholds
n/a
25 ops.
Buy Volume
n/a
5 ops.
Sell Volume
22Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 26,244 of 29,062 companies
21.6
score / 100
Value
12
Quality
31
FCF yld-15%
Earn yld-16%
EV/EBITDA·
ROE-117%
Gross mgn79%
Net mgn-98%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
젠큐릭스 es una empresa farmacéutica y de atención médica que cotiza en el mercado XKRX. Se especializa en el desarrollo de soluciones de diagnóstico innovadoras.